Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Drug

European Commission Grants Conditional Approval for Janssen’s Talvey in Multiple Myeloma

Fineline Cube Aug 23, 2023

The European Commission (EC) has granted conditional approval to Johnson & Johnson’s (J&J; NYSE: JNJ)...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Fluzoparib Files for New Indication with China’s NMPA

Fineline Cube Aug 23, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that the National Medical Products...

Company Drug

Kintor Pharmaceutical Completes Enrollment in Phase II Study of GT20029 for Androgenetic Alopecia

Fineline Cube Aug 23, 2023

China-based Kintor Pharmaceutical Limited (HKG: 9939) has announced the completion of patient enrollment in a...

Company Drug

Novartis’s Leqvio (Inclisiran) Approved in China for Hypercholesterolemia Treatment

Fineline Cube Aug 23, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has received approval from the National Medical Products Administration...

Company Drug

Novatim’s KQ-2003 and KY-0118 Advance with Clinical Trial Approvals in China

Fineline Cube Aug 22, 2023

China-based cancer immunotherapy specialist Novatim Immune Therapeutics (Zhejiang) Co., Ltd has recently obtained clinical trial...

Company Drug

Sichuan Huiyu Pharmaceutical’s Plerixafor Gains Marketing Approval from Italian Medicines Agency

Fineline Cube Aug 22, 2023

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...

Company Medical Device

Lifetech Scientific Corporation Receives NMPA Approval for Epione Navigation System

Fineline Cube Aug 22, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received market approval from...

Company Deals

Jiahui Health and Gleneagles Hong Kong Hospital Partner for Integrated Healthcare Services

Fineline Cube Aug 22, 2023

China-based Jiahui Health has entered into a strategic partnership with Gleneagles Hong Kong Hospital to...

Company Deals

Saints Sages Surgical Secures Series B Funding to Advance Energy-Based Devices

Fineline Cube Aug 22, 2023

Shanghai-based Saints Sages Surgical Co., Ltd, a leading developer of high-value minimally invasive surgical products,...

Company Drug

Hainan Huluwa Pharmaceutical Gets NMPA Approval for Generic Briviact Clinical Study

Fineline Cube Aug 22, 2023

China-based Hainan Huluwa Pharmaceutical Group Co., Ltd (SHA: 605199) has announced that it has received...

Company Deals

CSPC Pharmaceutical Group Partners with Insilico and XtalPi for AI-Driven Drug R&D

Fineline Cube Aug 22, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced strategic partnership agreements with Insilico Medicine...

Company Drug

Luye Pharma Group Submits Market Approval Filing for Lurbinectedin in Metastatic SCLC in Macau

Fineline Cube Aug 22, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing has been...

Company Medical Device

magAssist Receives FDA Breakthrough Device Designation for NyokAssist VAD

Fineline Cube Aug 22, 2023

magAssist, a firm based in Suzhou, China, has announced that it has received breakthrough device...

Company Drug

Auzone Biological Technology Gets FDA Approval for Edaravone Oral Preparations in ALS

Fineline Cube Aug 22, 2023

Suzhou Auzone Biological Technology Co., Ltd. has received approval from the US Food and Drug...

Company

RemeGen Ltd Reports 20.56% YOY Revenue Growth in H1 2023 Financial Results

Fineline Cube Aug 22, 2023

China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has released its financial report for the first...

Company Drug

Gilead’s Magrolimab Phase III Trial for AML Faces Partial Hold by FDA

Fineline Cube Aug 22, 2023

Gilead (NASDAQ: GILD) has announced that the US Food and Drug Administration (FDA) has imposed...

Company

Ascentage Pharma’s 2023 Interim Report: 49% YOY Revenue Growth and Market Expansion

Fineline Cube Aug 22, 2023

China-based Ascentage Pharma (HKG: 6855) has released its 2023 interim financial report, revealing a 49%...

Company Drug

Pfizer’s RSV Vaccine Abrysvo Receives FDA Authorization for Maternal Immunization

Fineline Cube Aug 22, 2023

The US Food and Drug Administration (FDA) has authorized the use of Pfizer’s (NYSE: PFE)...

Company Drug

J&J’s Teclistamab Granted Priority Review in China for Relapsed Multiple Myeloma

Fineline Cube Aug 22, 2023

The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson’s (J&J, NYSE:...

Company

Ascletis Pharma Inc. Reports 21.7% Revenue Increase in H1 2023, Led by Ritonavir Sales

Fineline Cube Aug 22, 2023

China-based Ascletis Pharma Inc., (HKG: 1672) has revealed revenues of RMB 46.51 million (USD 6.38...

Posts pagination

1 … 537 538 539 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.